Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sustained remission and productivity outcomes with etanercept plus methotrexate in early rheumatoid arthritis
2008-002623-85Phase 4Completed
- Sponsor
- Wyeth
- Start
- May 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Etanercept 25 mg once weekly + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: Sustained remission rate. Started May 2009; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-002623-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002623-85.